Recent Company News

• 10:06 AM ET Aug 19, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (74 total)

• 08:44 AM ET Aug 18, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 04:33 PM ET Aug 18, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 01:17 AM ET Aug 18, 2025
  

  Novartis to present 19 abstracts across its cardiovascular portfolio at ESC Congress (CHF 99.49, 0.00)

• 06:08 AM ET Aug 14, 2025
  

  StreetAccount Macro Headlines:

• 01:21 AM ET Aug 12, 2025
  

  Novartis ianalumab Phase III trial meets primary endpoint in immune thrombocytopenia ITP, demonstrating statistically significant improvement in time to treatment failure (CHF 96.02, 0.00)

• 10:29 AM ET Aug 11, 2025
  

  StreetAccount M&A Summary: Week of 4-Aug

• 09:18 AM ET Aug 11, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 06:53 AM ET Aug 11, 2025
  

  Healthcare, telecom and insurance best performers; industrials, utilities the big laggards: